Rebecca Strawbridge

ORCID: 0000-0002-2984-1124
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bipolar Disorder and Treatment
  • Tryptophan and brain disorders
  • Treatment of Major Depression
  • Schizophrenia research and treatment
  • Stress Responses and Cortisol
  • Electroconvulsive Therapy Studies
  • Mental Health Research Topics
  • Adolescent and Pediatric Healthcare
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Maternal Mental Health During Pregnancy and Postpartum
  • Mental Health Treatment and Access
  • Functional Brain Connectivity Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • COVID-19 and healthcare impacts
  • Electrolyte and hormonal disorders
  • Health, psychology, and well-being
  • Child and Adolescent Psychosocial and Emotional Development
  • COVID-19 and Mental Health
  • Psychosomatic Disorders and Their Treatments
  • Glycogen Storage Diseases and Myoclonus
  • Long-Term Effects of COVID-19
  • Family Support in Illness
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Cardiac Health and Mental Health
  • Dermatology and Skin Diseases

King's College London
2016-2025

Milken Institute
2023

University of Michigan
2023

Brigham and Women's Hospital
2023

University of Oslo
2023

Oslo University Hospital
2023

National Institute for Health Research
2019-2022

South London and Maudsley NHS Foundation Trust
2016-2022

Centre for Mental Health
2019

Maudsley Hospital
2019

Abstract Objectives To understand treatment practices for bipolar disorders (BD), this study leveraged the Global Bipolar Cohort collaborative network to investigate pharmacotherapeutic patterns in multiple cohorts of well‐characterized individuals with BD North America, Europe, and Australia. Methods Data on pharmacotherapy, demographics, diagnostic subtypes, comorbidities were provided from each participating cohort. Individual site regional pooled proportional meta‐analyses generalized...

10.1111/bdi.13366 article EN cc-by Bipolar Disorders 2023-07-18

Background Mood disorders, i.e. major depressive disorder (MDD) and bipolar are leading sources of disability worldwide. Currently available treatments do not yield remission in approximately a third patients with mood disorder. This is part because these target specific core pathology underlying heterogeneous disorders. In recent years, abnormal inflammatory processes have been identified as putative pathophysiological mechanisms treatment targets particularly among individuals...

10.1192/bjo.2020.43 article EN cc-by-nc-nd BJPsych Open 2020-06-05

Cognitive remediation therapy (CRT) may benefit people with bipolar disorder type I and II for whom cognitive impairment is a major contributor to disability. Extensive research has demonstrated CRT improve cognition psychosocial functioning in different diagnoses, but randomised trials of evidenced programmes are lacking disorders. The Remediation Bipolar (CRiB) study aimed determine whether an established programme feasible acceptable disorders.This proof-of-concept, single-blind trial...

10.1111/bdi.12968 article EN cc-by Bipolar Disorders 2020-06-25

Persistent functional impairment is common in bipolar disorder (BD) and influenced by a number of demographic, clinical, cognitive features. The goal this project was to estimate compare the influence key factors on community function multiple cohorts well-characterized samples individuals with BD.Thirteen from 7 countries included n = 5882 BD across sites. statistical approach consisted systematic uniform application analyses Each site performed logistic regression analysis empirically...

10.1111/bdi.13208 article EN cc-by-nc-nd Bipolar Disorders 2022-03-24

Abstract Background Despite well-established guidelines for managing major depressive disorder, its extensive disability burden persists. This Value of Treatment mission from the European Brain Council aimed to elucidate nature and extent “gaps” between best-practice current-practice care, specifically to: 1. Identify current treatment gaps along care pathway determine these in comparison with stepped-care model 2. Recommend policies intending better meet patient needs (i.e., minimize gaps)....

10.1192/j.eurpsy.2022.28 article EN cc-by-nc-nd European Psychiatry 2022-01-01

(Originally published and reprinted with permission Dove Medical Press Ltd., from Neuropsychiatric Disease Treatment 2017;13:1245-1262).

10.1176/appi.focus.16206 article EN FOCUS The Journal of Lifelong Learning in Psychiatry 2018-04-01

Threat avoidance is a prominent symptom of affective disorders, yet its biological basis remains poorly understood. Here, we used validated task, the Joystick Operated Runway Task (JORT), combined with fMRI, to explore whether abnormal function in neural circuits responsible for underlies these symptoms. Eighteen individuals major depressive disorder (MDD) and 17 unaffected controls underwent which involved using physical effort avoid threatening stimuli, paired mild electric shocks on...

10.1017/pen.2022.1 article EN cc-by-nc-nd Personality Neuroscience 2022-01-01

Objective Lithium, despite its evidence base and range of indications, is often underutilized due to safety concerns associated with high-dose prescriptions consequent necessity for regular blood monitoring. Emerging suggests potential benefits at lower doses, especially pro-cognitive effects positive profile. While accessible as a supplement, empirical human on neuropsychiatric lacking. This study aimed provide preliminary regarding the utilization perceived low-dose lithium supplements...

10.1177/07067437251328282 article EN The Canadian Journal of Psychiatry 2025-03-28

ABSTRACT CBT is effective for Bipolar Disorder (BD), however there often poor access. Despite IAPT‐SMI pilot sites, has been no roll out of BD in NHS Talking Therapies Services. This study aimed to examine the extent which seen these services. A survey was conducted 147 service users with and 106 staff. freedom information request also responded by 48 trusts. Forty‐nine percent those had tried access Therapies, this being before a formal diagnosis 42% who 29% were told that they could not be...

10.1002/mhs2.70016 article EN cc-by Mental Health Science 2025-04-07
Coming Soon ...